Abstract
Mucormycosis represents the second most frequent invasive mold infection after invasive aspergillosis and its incidence tends to increase around the world [1]. The disease not only affects patients with severe immune defects (e.g. hematologic cancer patients, transplant recipients), but also apparently immunocompetent individuals, such as those with uncontrolled diabetes, sequela of tuberculosis, chronic kidney disease or following severe trauma [1,2]. For these reasons, the burden of mucormycosis is particularly high in low- and middle-income countries with limited access to healthcare structures.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
